

Trastuzumab emtansine (T-DM1) EMILIA

### PRELIMINARY SCORE

#### CURATIVE



#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



Delayed deterioration in global QoL

#### Serious and disabling adverse effects



#### Other adjustments



Early stopping or crossover

Trastuzumab emtansine (T-DM1) EMILIA

### SCORE

#### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response


#### NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Therapeutic Indication: As a single agent for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy

Experimental Arm: Trastuzumab emtansine (T-DM1)

Control Arm: Lapatinib + capecitabine



